Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
about
Maternal vasodilation in pregnancy: the emerging role of relaxinG-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and preventionAgents with vasodilator properties in acute heart failure: how to design successful trialsThe relaxin receptor (RXFP1) utilizes hydrophobic moieties on a signaling surface of its N-terminal low density lipoprotein class A module to mediate receptor activation.Silent disease progression in clinically stable heart failure.Relaxin is a potent renal vasodilator in conscious rats.A vasoactive role for endogenous relaxin in mesenteric arteries of male mice.Protective effect of relaxin in cardiac anaphylaxis: involvement of the nitric oxide pathway.Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide.Relaxin protects astrocytes from hypoxia in vitro.Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heartEmerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsiaUnveiling the vasodilatory actions and mechanisms of relaxinBasic progress and future therapeutic perspectives of relaxin in ischemic heart disease.Relaxin is essential for renal vasodilation during pregnancy in conscious ratsCellular retrograde cardiomyoplasty and relaxin therapy for postischemic myocardial repair in a rat modelSerum relaxin levels as a novel biomarker for detection of acute myocardial infarctionNew Insights into biological roles of relaxin and relaxin-related peptides.Cardiac anaphylaxis: pathophysiology and therapeutic perspectives.Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cellsProtection from cigarette smoke-induced vascular injury by recombinant human relaxin-2 (serelaxin)Relaxin as a natural agent for vascular healthVasodilators in the treatment of acute heart failure: what we know, what we don't.Relaxin, a pleiotropic vasodilator for the treatment of heart failure.Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatmentRole of relaxin in maternal systemic and renal vascular adaptations during gestation.Mast cells, peptides and cardioprotection - an unlikely marriage?Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation.Novel neurohormonal insights with therapeutic potential in chronic heart failure.Relaxin: new pathophysiological aspects and pharmacological perspectives for an old protein.Serelaxin : a potential new drug for the treatment of acute heart failure.Targeting the relaxin hormonal pathway in prostate cancer.Relaxin' the Heart: A Novel Therapeutic Modality.Vascular actions of relaxin: nitric oxide and beyond.Does serelaxin treatment alter passive mechanical wall properties in small resistance arteries?Relaxin pretreatment decreases infarct size in male rats after middle cerebral artery occlusion.Prominent role of relaxin in improving postinfarction heart remodeling.Relaxin stimulates leukocyte adhesion and migration through a relaxin receptor LGR7-dependent mechanism.
P2860
Q24618633-775AB068-3415-46E8-AA61-42CA5A7BB694Q26744192-215F506E-8730-481E-A91B-2AF07FC7874AQ28084239-169C5B68-837B-40B3-8BF5-60C9B808AD93Q30352669-CFC1AD1C-A6D5-4214-B092-A5DCBCABDBFDQ33578212-1CCAD15C-8519-4205-9ACD-A2020255E226Q33843076-211F4799-9E84-47C5-A83B-1205536DF7CEQ34226848-5D0561C3-CA77-48DF-979C-F96773EC996DQ35044621-0A8B406D-4384-453B-813C-23D2E8DF71FBQ35046881-D769DB7F-0C49-4540-9112-5CD57E87C0DAQ35112071-4D5B04F0-7170-4C4D-AB64-550BD3E00402Q35120364-00ADE66F-EABE-4ED1-8A4C-C9A802F614DAQ35383835-3A4C5693-7A8A-44A3-A132-0446B2889431Q35765401-3AC0E868-77BD-4C90-AE08-6C976EE0F65EQ36054390-2993BC49-37AB-426F-B18C-720F4C1B94FEQ36084530-D992BDAA-66E2-4234-8A43-5C161E377E97Q36163310-8AC58569-47DE-436D-AA94-27F58ACD6FF6Q36167196-BF9B40DF-6404-46E3-A2EE-D317F784750CQ36176574-D67FB5BA-793C-48B2-9B3E-01D887190C76Q36318249-F04F88BB-B003-4646-95CB-F3B6E3933E78Q36324350-92A26360-AB1B-44E8-9D7B-80674797F979Q36395739-06C22849-3DC1-47E6-81F3-D11AB7F61F23Q36506903-17422BC8-AD00-4DA3-9C9C-238BFFE64915Q36797528-DAF96F15-6BDB-40B2-87C4-2E237BA09A93Q36835818-F6B67CDB-5CA4-45F1-8936-2239F9A14BB7Q37355110-219D7E8C-3C9A-4F1E-ACFB-05E1BF4EC820Q37356318-F448A3B4-AEF9-415A-A500-92D8F95F20C1Q37405208-45E663F8-3FA1-47AC-835D-B7A375741619Q37470800-D2B9D0E6-A4A7-4E45-96FC-DDFCF2396BB8Q37536258-A035F6F6-11D2-4F21-AB06-2AFCF9FD8A5BQ37648577-F75CEA50-8585-4644-AE8D-0D2879BA6444Q37749836-703A133D-5741-4AD8-822B-998FD0D0623AQ38080804-8A070A4C-EAE5-4F16-BA6E-DFFC164F5D06Q38215304-43CBA563-CB3E-4ADD-A0D8-9EEF60B6692EQ38231840-D1C471EA-9136-40BE-9C0F-EB539BFDCC35Q38940630-08E97A4B-FE79-4E91-B859-36365F714997Q38945156-4C5AF79E-8258-4748-BFCE-1439A8F6E55DQ38960703-22576F9D-884D-4DD6-9FA3-E2DD40F2D8FDQ39720492-BA999FCB-2C78-4B65-8271-E9C362102BF8Q39856633-D15C5BA6-45FA-4DAD-8192-41BDB2B185DEQ40348456-21E39CA1-8CAC-416E-8894-793AB235D067
P2860
Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
@ast
Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
@en
type
label
Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
@ast
Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
@en
prefLabel
Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
@ast
Relaxin-induced increased coronary flow through stimulation of nitric oxide production.
@en
P2093
P2860
P1476
Relaxin-induced increased coronary flow through stimulation of nitric oxide production
@en
P2093
P F Mannaioni
T Bani-Sacchi
P2860
P304
P356
10.1111/J.1476-5381.1995.TB16377.X
P407
P50
P577
1995-09-01T00:00:00Z